These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

104 related articles for article (PubMed ID: 12952305)

  • 21. Angiogenesis factors in gliomas: a new key to tumour therapy?
    Mentlein R; Held-Feindt J
    Naturwissenschaften; 2003 Sep; 90(9):385-94. PubMed ID: 14504780
    [TBL] [Abstract][Full Text] [Related]  

  • 22. HA1077, a Rho kinase inhibitor, suppresses glioma-induced angiogenesis by targeting the Rho-ROCK and the mitogen-activated protein kinase kinase/extracellular signal-regulated kinase (MEK/ERK) signal pathways.
    Nakabayashi H; Shimizu K
    Cancer Sci; 2011 Feb; 102(2):393-9. PubMed ID: 21166955
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Tumor angiogenesis and anti-angiogenic therapy in malignant gliomas revisited.
    Plate KH; Scholz A; Dumont DJ
    Acta Neuropathol; 2012 Dec; 124(6):763-75. PubMed ID: 23143192
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Endogenous inhibitors of angiogenesis in malignant gliomas: nature's antiangiogenic therapy.
    Rege TA; Fears CY; Gladson CL
    Neuro Oncol; 2005 Apr; 7(2):106-21. PubMed ID: 15831230
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Antiangiogenic strategies for treatment of malignant gliomas.
    Chi AS; Norden AD; Wen PY
    Neurotherapeutics; 2009 Jul; 6(3):513-26. PubMed ID: 19560741
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Anti-angiogenic treatment strategies for malignant brain tumors.
    Kirsch M; Schackert G; Black PM
    J Neurooncol; 2000; 50(1-2):149-63. PubMed ID: 11245274
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Next-Generation Anti-Angiogenic Therapies as a Future Prospect for Glioma Immunotherapy; From Bench to Bedside.
    Shamshiripour P; Hajiahmadi F; Lotfi S; Esmaeili NR; Zare A; Akbarpour M; Ahmadvand D
    Front Immunol; 2022; 13():859633. PubMed ID: 35757736
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Angiogenesis: molecular mechanisms of activation, promotion and maintenance.
    Bikfalvi A
    J BUON; 2007 Sep; 12 Suppl 1():S59-66. PubMed ID: 17935279
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Glioma angiogenesis: Towards novel RNA therapeutics.
    Würdinger T; Tannous BA
    Cell Adh Migr; 2009; 3(2):230-5. PubMed ID: 19262177
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Molecular biomarker-guided anti-angiogenic targeted therapy for malignant glioma.
    Yan C; Wang J; Yang Y; Ma W; Chen X
    J Cell Mol Med; 2019 Aug; 23(8):4876-4882. PubMed ID: 31210419
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Adhesion molecules and the extracellular matrix as drug targets for glioma.
    Shimizu T; Kurozumi K; Ishida J; Ichikawa T; Date I
    Brain Tumor Pathol; 2016 Apr; 33(2):97-106. PubMed ID: 26992378
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Temozolomide/PLGA microparticles plus vatalanib inhibits tumor growth and angiogenesis in an orthotopic glioma model.
    Zhang YH; Yue ZJ; Zhang H; Tang GS; Wang Y; Liu JM
    Eur J Pharm Biopharm; 2010 Nov; 76(3):371-5. PubMed ID: 20816959
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Salinomycin exhibits anti-angiogenic activity against human glioma in vitro and in vivo by suppressing the VEGF-VEGFR2-AKT/FAK signaling axis.
    Bi YL; Mi PY; Zhao SJ; Pan HM; Li HJ; Liu F; Shao LR; Zhang HF; Zhang P; Jiang SL
    Int J Mol Med; 2017 May; 39(5):1255-1261. PubMed ID: 28358414
    [TBL] [Abstract][Full Text] [Related]  

  • 34. [VEGFRs in neoplastic angiogenesis and prospects for therapy of brain tumors].
    Korchagina AA; Shein SA; Gurina OI; Chekhonin VP
    Vestn Ross Akad Med Nauk; 2013; (11):104-14. PubMed ID: 24640739
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The anti-angiogenic role of soluble-form VEGF receptor in malignant gliomas.
    Takano S; Ishikawa E; Matsuda M; Sakamoto N; Akutsu H; Yamamoto T; Matsumura A
    Int J Oncol; 2017 Feb; 50(2):515-524. PubMed ID: 28000842
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Evidence that Cereport's ability to increase permeability of rat gliomas is dependent upon extent of tumor growth: implications for treating newly emerging tumor colonies.
    Bartus RT; Snodgrass P; Dean RL; Kordower JH; Emerich DF
    Exp Neurol; 2000 Jan; 161(1):234-44. PubMed ID: 10683290
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Biochanin A inhibits endothelial cell functions and proangiogenic pathways: implications in glioma therapy.
    Jain A; Lai JC; Bhushan A
    Anticancer Drugs; 2015 Mar; 26(3):323-30. PubMed ID: 25501542
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Combination treatment with temozolomide and thalidomide inhibits tumor growth and angiogenesis in an orthotopic glioma model.
    Son MJ; Kim JS; Kim MH; Song HS; Kim JT; Kim H; Shin T; Jeon HJ; Lee DS; Park SY; Kim YJ; Kim JH; Nam DH
    Int J Oncol; 2006 Jan; 28(1):53-9. PubMed ID: 16327979
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Therapeutic application of noncytotoxic molecular targeted therapy in gliomas: growth factor receptors and angiogenesis inhibitors.
    Idbaih A; Ducray F; Sierra Del Rio M; Hoang-Xuan K; Delattre JY
    Oncologist; 2008 Sep; 13(9):978-92. PubMed ID: 18779539
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Identification of two novel Chlorotoxin derivatives CA4 and CTX-23 with chemotherapeutic and anti-angiogenic potential.
    Xu T; Fan Z; Li W; Dietel B; Wu Y; Beckmann MW; Wrosch JK; Buchfelder M; Eyupoglu IY; Cao Z; Savaskan NE
    Sci Rep; 2016 Feb; 6():19799. PubMed ID: 26831010
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 6.